Sigyn Therapeutics, Inc.
Datakwaliteit: 83%
SIGY
OTC
Manufacturing
Measuring & Analyzing Instruments
€ 0,03
▲
€ 0,01
(36,00%)
Marktkapitalisatie: 54.582,0
Prijs
€ 0,03
Marktkapitalisatie
54.582,0
Dagbereik
€ 0,02 — € 0,03
52-Weeksbereik
€ 0,01 — € 5,00
Volume
111.291
Openen € 0,03
50D / 200D Gem.
€ 0,29
88,35% below
50D / 200D Gem.
€ 1,93
98,24% below
Quick Summary
Belangrijkste Punten
Negative free cash flow of -936.426,0
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio0,02
Interest CoverageN/A
Waardering
PE (TTM)
-0,02
Boven sectorgemiddelde (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 0,0 | -1,5 |
| P/B | — | 1,6 |
| ROE % | — | -53,4 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -3,22 M |
| ROE | N/A | ROA | -3438,93% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -936.426,0 |
| ROIC | N/A | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0,02 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | -3,90 M | Tangible Book Value | -5,92 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0,02 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -1715,63% | ||
| Market Cap | 54.582,0 | Enterprise Value | 3,82 M |
| Per Share | |||
| EPS (Diluted TTM) | -1,93 | Revenue / Share | N/A |
| FCF / Share | -0,58 | OCF / Share | -0,58 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 29,07% |
| SBC-Adj. FCF | -1,12 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -3,34 M | -4,15 M | -2,93 M | -3,00 M | -1,26 M |
| EPS (Diluted) | -2,51 | -3,77 | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -2,52 M | -2,46 M | -2,15 M | -2,01 M | -916.434,0 |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 773.279,0 | 798.165,0 | 657.657,0 | 734.014,0 | 27.456,0 |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | — | — | 30.800,0 | 30.800,0 | 343.156,0 |
| Income Tax | — | — | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 213.719,0 | 321.806,0 | 332.879,0 | 710.259,0 | 694.082,0 |
| Total Liabilities | 4,67 M | 3,73 M | 2,24 M | 974.843,0 | 594.903,0 |
| Shareholders' Equity | -4,46 M | -3,41 M | -1,90 M | -264.584,0 | 99.179,0 |
| Total Debt | 2,20 M | 2,51 M | 2,28 M | — | — |
| Cash & Equivalents | 12.144,0 | 11.690,0 | 8.356,0 | 340.956,0 | 84.402,0 |
| Current Assets | 21.244,0 | 118.063,0 | 70.298,0 | 393.031,0 | 670.449,0 |
| Current Liabilities | 4,61 M | 3,61 M | 2,05 M | 734.218,0 | 594.903,0 |
{"event":"ticker_viewed","properties":{"ticker":"SIGY","listing_kind":"stock","pathname":"/stocks/sigy","exchange":"OTC","country":"US"}}